Wednesday, June 10, 2026
🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
2,004

Quick answer

2,004 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 8940288

    Method for treating cancer by administering IL-15 and IL-15Ralpha complexes

    UNIVERSITY OF CONNECTICUT · Granted Tue Jan 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8940301

    Breast tumor treatment with anti-CXCR1 compositions

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Jan 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8940871

    Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting

    The Regents of the University of California · Granted Tue Jan 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8940701

    Compounds for, and methods of, treating cancer and inhibiting invasion and metastases

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Jan 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8940298

    High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection

    The Regents of the University of California · Granted Tue Jan 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. AU 2013283318

    Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders

    4SC DISCOVERY GMBH [DE] · Granted Thu Jan 22 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8936941

    Compositions useful for cancer detection and treatment, a cancer stem cell model, and methods of production and use thereof

    The Board of Regents of the University of Oklahoma · Granted Tue Jan 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8932588

    Treatment of cancer involving mutated KRAS or BRAF genes

    TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue Jan 13 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8933041

    System for treating and preventing breast cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jan 13 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8927215

    GNA11 mutations in melanoma

    The Regents of the University of California · Granted Tue Jan 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8927506

    Acetates of 2-deoxy monosaccharides with anticancer activity

    The Board of Regents of the University of Texas System · Granted Tue Jan 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8920799

    Methods of treating cancer by administering an Axl ligand-binding portion of an Axl tyrosine kinase receptor extracellular domain

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Dec 30 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8920800

    Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins

    Five Prime Therapeutics, Inc. · Granted Tue Dec 30 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8921050

    Methods of diagnosing renal cell carcinoma

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 30 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8912214

    Use of Chk2 kinase inhibitors for cancer treatment

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 16 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8901279

    Humanized antibodies with anti-tumor activity

    TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue Dec 02 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8901093

    Custom vectors for treating and preventing pancreatic cancer

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Dec 02 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8901171

    Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent

    Takeda Pharmaceutical Company Limited · Granted Tue Dec 02 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8883161

    Fusion polypeptide against EB virus-induced tumor and colicin Ia mutant

    PROTEIN DESIGN LAB, LTD. · Granted Tue Nov 11 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8883500

    Method of preparing adenosine-resistant anti-tumor T lymphocytes for adoptive immunotherapy

    Northwestern University · Granted Tue Nov 11 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8877765

    Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Nov 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8877718

    Antiinfective and antitumoral compounds isolated from tropical lianas

    Julius-Maximilians-Universitat Wurzburg · Granted Tue Nov 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8877204

    Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes

    University of Connecticut Health Center · Granted Tue Nov 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8865873

    Internalizing human monoclonal antibodies targeting prostate cancer cells in situ

    The Regents of the University of California · Granted Tue Oct 21 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8865748

    Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer

    Akebia Therapeutics, Inc. · Granted Tue Oct 21 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8859527

    Inclusion complex of deoxypodophyllotoxin of cyclodextrin, preparation method, use for treatment of cancer thereof

    CHINA PHARMACEUTICAL UNIVERSITY · Granted Tue Oct 14 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8853277

    Nitroxide therapy for the treatment of von Hippel—Lindau disease (VHL) and renal clear cell carcinoma (RCC)

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 07 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8846629

    Id-1 and Id-2 genes and products as therapeutic targets for treatment of breast cancer and other types of carcinoma

    The Regents of the University of California · Granted Tue Sep 30 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 8840886

    Method of treating cancer with DLL4 antagonist and chemotherapeutic agent

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 23 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8835167

    Humanized anti-tag 72 CC49 for diagnosis and therapy of human tumors

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Sep 16 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8835613

    β-mannosylceramide and stimulation of NKT cell anti-tumor immunity

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 16 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 8834938

    Use of arsenic for cancer therapy protection

    The Board of Regents of the University of Texas System · Granted Tue Sep 16 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8835493

    Oligo-benzamide compounds for use in treating cancers

    The Board of Regents of the University of Texas System · Granted Tue Sep 16 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. CA 2903132

    CABAZITAXEL ET SON UTILISATION POUR LE TRAITEMENT DES CANCERS DE LA PROSTATE METASTATIQUES

    AVENTIS PHARMA SA [FR] · Granted Fri Sep 12 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Thu Sep 07 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 8829025

    Anti-cancer compounds

    Northwestern University · Granted Tue Sep 09 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 8821880

    Methods and agents for the diagnosis and treatment of hepatocellular carcinoma

    China Synthetic Rubber Corporation · Granted Tue Sep 02 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 28 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8822196

    Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 02 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 28 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8816059

    Method for predicting and detecting tumor metastasis

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 26 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 21 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8815830

    Nucleosides with antiviral and anticancer activity

    Regents of the University of Minnesota · Granted Tue Aug 26 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 21 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8815240

    Methods and agents for the diagnosis and treatment of hepatocellular carcinoma

    China Synthetic Rubber Corporation · Granted Tue Aug 26 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 21 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8809291

    Id-1 gene and gene products as therapeutic targets for treatment of breast cancer and other types of carcinoma

    The Regents of the University of California · Granted Tue Aug 19 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8809502

    Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Aug 19 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8808698

    Methods for inhibition of lymphangiogenesis and tumor metastasis

    The Regents of the University of California · Granted Tue Aug 19 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8802689

    Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases

    The Regents of the University of California · Granted Tue Aug 12 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 07 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8802090

    Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

    PRECISION BIOLOGICS, INC. · Granted Tue Aug 12 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 07 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8795964

    GRM3 mutations and use thereof for the diagnosis and treatment of melanoma

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 05 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 31 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8795738

    Use of arsenic for cancer therapy protection

    The Board of Regents of the University of Texas System · Granted Tue Aug 05 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 31 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8790878

    Diagnosis and treatment of breast cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Jul 29 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

2,004 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.